drugset
drugset / Trial / NCT03687073

Trial of Indole-3-Carbinol and Silibinin

NCT03687073 ↗

Phase 1 Completed 21 enrolled Masonic Cancer Center, University of Minnesota
RandomizedSequentialOpen-labelTreatment

Summary

This is a non-therapeutic, Phase 1 clinical trial to examine the safety, pharmacokinetic (PK) characteristics, and pharmacodynamics (PD) effect of indole-3-carbinol (I3C) and silibinin (Sil) in healthy subjects.

Timeline

Start
2018-11-29
Primary completion
2021-05-07
Completion
2021-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Indole-3-carbinol Small molecule 400 mg Oral
Subject Silymarin Traditional medicine (herbal / TCM) 360 mg —
Subject Silymarin Traditional medicine (herbal / TCM) 720 mg —

Indications

No indication recorded.